Mate (GoodnightMate) specializes in premature ejaculation treatment, offering prescription and OTC solutions designed to help men last longer.
We earn commissions from the providers listed here. No provider buys a position, a rating, or a listing. The order is set by hand, and we do not claim it is independent of what we earn. Advertising Disclosure


Complete 2026 Comparison for Premature Ejaculation
Mate is our overall pick for premature ejaculation, based on our rating and feature coverage.
Mate (GoodnightMate) specializes in premature ejaculation treatment, offering prescription and OTC solutions designed to help men last longer.
UrWay Health offers telehealth services for weight loss and sexual wellness, with a focus on GLP-1 weight loss medications and men's health treatments.
We don't list UrWay Health, and we earn nothing if you choose it.
| Feature | ||
|---|---|---|
| Rating | 9/10 | 9/10 |
| Founded | 2020 | 2021 |
| Free Consultation | Yes | Yes |
| Free Shipping | Yes | Yes |
| Accepts Insurance | No | No |
| HSA/FSA Accepted | Yes | Yes |
| Mobile App | No | No |
| Consultation Type | Asynchronous | Video, Asynchronous |
| Shipping Time | 3-5 business days | 5-7 business days |
| Treatment | ||
|---|---|---|
| Premature Ejaculation | $48/month | N/A |
These notes are not a medical screening: a licensed provider decides after an intake review whether a treatment is appropriate for you.
The better choice depends on your specific needs and priorities. Mate carries a 9/10 rating in our provider database and is listed as a fit for men specifically seeking pe treatment. UrWay Health is listed as a fit for patients seeking weight loss treatment. Those scores are our own editorial ratings, not third-party review averages. Mate was founded in 2020 in Austin, TX, while UrWay Health was founded in 2021 in Miami, FL. Both are US telehealth platforms that connect you with licensed providers, and which one suits you is a question for that provider.
Pricing varies by treatment category. Mate starts at $48/month. UrWay Health pricing varies. These are the rates last recorded in our provider database, so confirm the current price at checkout before you enroll. Mate lists free consultations. UrWay Health lists free consultations. Mate lists free shipping. UrWay Health lists free shipping. Mate and UrWay Health list HSA and FSA payment options, though whether a given charge is eligible depends on your plan and on IRS rules for that expense.
Mate does not list health insurance as accepted, and operates on a cash-pay model with published pricing. UrWay Health does not list insurance as accepted. Mate and UrWay Health list HSA and FSA payment options; eligibility for any specific charge depends on your plan and IRS rules, so check with your plan administrator first. Coverage and pricing change, so confirm both with the platform and your insurer before you enroll.
Both are established US telehealth platforms. Mate was founded in 2020 and is headquartered in Austin, TX. UrWay Health was founded in 2021 in Miami, FL. Both state that they work with US-licensed providers and licensed pharmacies and that they operate under HIPAA. We do not independently audit provider credentials or pharmacy licensing, so if you want that confirmed, you can look up an individual prescriber through your state medical board and a pharmacy through your state board of pharmacy.
Mate offers asynchronous consultations (free). UrWay Health provides video and asynchronous consultations (free). On both, you complete a health questionnaire online that a licensed provider reviews. Video consultations are available if you prefer to speak with a provider face to face. Turnaround times vary by platform, by state, and by how busy the provider network is, and you can message your provider with follow-up questions through the platform.
Mate lists shipping within 3-5 business days with free standard shipping. UrWay Health lists shipping within 5-7 business days with free standard shipping. Both describe discreet packaging, and medications ship from licensed pharmacies rather than from the platform itself. Actual delivery time depends on your state, the pharmacy, and whether your prescription needs follow-up.
Mate requires a subscription for most treatments and lists cancellation at any time without a fee. UrWay Health also uses a subscription model and lists no cancellation penalty. Cancellation terms are set by each platform and can change, so read the current terms before you enroll. As a general rule you need to cancel before your next billing date to avoid the following period's charge, and anything already shipped is still yours.
Mate lists Prescription PE Medication, Topical Treatments, Combination Therapy starting at $48/month. UrWay Health lists PE Medications, Topical Treatments starting at prices that vary. Common approaches are an SSRI such as sertraline, which is prescribed off-label for premature ejaculation and is not FDA-approved for that use, and topical numbing sprays or creams containing lidocaine or benzocaine. What you can compare here is price, format, and whether a prescription is involved. Which approach fits your situation, and whether an off-label prescription makes sense for you, is a decision for a licensed provider.
Side effects come from the medication, not from the platform, so this is mostly a question about the drug you end up on rather than about Mate versus UrWay Health. Reported effects vary by treatment: ED medications may cause headache, flushing, or nasal congestion; finasteride carries labeled sexual side effects that some men report persisting after they stop; GLP-1 medications commonly cause nausea, vomiting, and other gastrointestinal effects, especially when the dose goes up; SSRIs may cause drowsiness, nausea, or changes in appetite and sexual function. This is not the full list for any of them. Both platforms have licensed providers review your medical history and screen for contraindications, and you should read the medication guide and raise anything you notice with your provider.
Choose Mate if you prioritize: men specifically seeking pe treatment, those wanting prescription options. Choose UrWay Health if you prioritize: patients seeking weight loss treatment, men with pe concerns. Mate stands out for: PE treatment specialist. UrWay Health is known for: Dual focus on weight loss and men's health. Both are established telehealth platforms, so your choice mostly comes down to price, which treatments each one carries, and how you prefer to handle visits and refills.
The process is similar on both. For Mate: visit their website, select your treatment category, and complete a health questionnaire that a licensed provider reviews. For UrWay Health: follow the same kind of flow on their platform. Both ask for your medical history, current medications, and answers to health screening questions, and being straight with those answers is what lets the provider catch an interaction. If you are approved, the prescription goes to a licensed pharmacy and ships to you (often with free shipping). How long the whole thing takes depends on the platform, your state, and the pharmacy.
Mate carries a 9/10 rating in our provider database. Those are ManyTreatments editorial scores on a 10-point scale, not averages pulled from third-party review sites, and you can read how we build them on our how-we-rate page. What we weigh: Mate scores well on pe specialist focus, with only treats pe as the trade-off. For UrWay Health it is multiple treatment options, against newer company. If you want customer sentiment as well, check current listings on the review platforms directly, since those move.
Medical Disclaimer: The information on this page is for educational purposes only and is not medical advice. Always consult with a licensed healthcare provider before starting any treatment. Read our full medical disclaimer.
How we scoreOur 1 to 10 brand scores are our own editorial judgment. They are not aggregated from third-party review platforms and they are not the output of a scoring formula.
What a starting price isA starting price is the lowest figure a company lists for a category, not a quote. What you pay follows a clinician's review of your intake, and where a required membership or care plan sits alongside the medication we publish the two charges combined.
Reading a warning letterA close-out letter is FDA's record that it has evaluated a company's corrective actions, so the absence of one means the file is not closed on the public record, and nothing more than that.
Regulatory noticeRegulatory note (verified October 31, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter
Regulatory noticeRegulatory note (verified October 8, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. The letter also quotes three claims from the site, among them "Generic Zepbound, Mounjaro", along with site copy naming semaglutide and tirzepatide as the active ingredient in the brand medications. Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for Strut Health, LLC on October 8, 2026 it showed no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter